Skip to main content
SpringerLink
Log in

Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A

  • Case Report
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

An Erratum to this article was published on 01 April 2004

Abstract

The safety and efficacy of a recombinant factor VIII (rFVIII) preparation (Kogenate) for the treatment of bleeding episodes was studied in previously untreated patients (PUPs) with severe, moderate, and mild hemophilia A. Patient peripheral blood samples taken at baseline and at 3, 6, 9, 12,18, and 24 months after the first infusion were evaluated for FVIII inhibitor antibodies by the Bethesda assay, for antibodies formed against trace proteins derived from the rFVIII production process, and for general changes in laboratory test results. Samples for general laboratory testing were also drawn every 6 months after the first 24 months. Hemostatic efficacy was assessed by physicians, and adverse events were recorded throughout the study period. Forty-three PUPs (30 with FVIII:C <1%; 10 with FVIII:C 1%-5%; and 3 with FVIII:C >5%) aged 3 months to 32 years were enrolled at 33 centers in Japan. Patients were studied for a mean of 51 months (range, 11-80 months), and the mean exposure time was 83 days (range, 2-571 days). The incidence of occurrence of FVIII inhibitors was 34.9% (high responders [≥10 Bethesda U/mL], 11.6%; low responders [0.5->10 Bethesda U/mL],23.3%). The median cumulative exposure time of inhibitor detection was 12 days, indicating inhibitor development at an early stage after the start of infusion of this preparation. Hemostasis was achieved with a single dose of Kogenate in 94.8% of the 951 bleeding episodes recorded in the study. Transient increases in antibodies against baby hamster kidney proteins and antimouse immunoglobulin G were observed in 14.0% and 18.6% of patients, respectively. Anti-rFVIII seroconversion was observed in 18.6% of patients and only in patients with inhibitor antibodies. Antibody responses to trace proteins were not correlated with drug-related adverse events with the exception of FVIII activity inhibition in PUPs with anti-rFVIII seroconversion. These data indicate that Kogenate is safe and effective for the treatment of bleeding in PUPs with hemophilia A.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene.Nature. 1984;312:326–330.

    Article  PubMed  CAS  Google Scholar 

  2. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones.Nature. 1984;312:330–337.

    Article  PubMed  CAS  Google Scholar 

  3. Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A: Recombinant Factor VIII Study Group.N Engl J Med. 1990;323:1800–1805.

    Article  PubMed  CAS  Google Scholar 

  4. Yoshioka A. Advances in hemophilia and other coagulation disorders: recombinant factor VIII preparations.Int J Pediatr Hematol Oncol. 1994;1:491–497.

    Google Scholar 

  5. Fukui H, Yoshioka A, Shima M, et al. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.Int J Hematol. 1991;54:419–427.

    PubMed  CAS  Google Scholar 

  6. Fukui H, Mori K, Ishikawa M, et al. A long-term, multi-center clinical study of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A [in Japanese].Nihon Yuketsu Gakkai Zasshi. 1991;37:593–604.

    Google Scholar 

  7. Kasper CK, Aledort LM, Counts RB, et al. A more uniform measurement of factor VIII inhibitors [letter].Thromb Diath Haemorrh. 1975;34:869–872.

    Google Scholar 

  8. Shima M, Sawamoto Y, Nakai H, et al. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII: Kogenate Japanese Clinical Study Group.Int J Hematol. 1995;62:35–43.

    Article  PubMed  CAS  Google Scholar 

  9. McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII inhibitors in patients with hemophilia A: a national cooperative study, II: observations on the initial development of factor VIII:C inhibitors.Blood. 1988;71:344–348.

    PubMed  CAS  Google Scholar 

  10. Sultan Y. Prevalence of inhibitors in a population of 3435 hemophilia patients in France: French Hemophilia Study Group.Thromb Haemost. 1992;67:600–602.

    Article  PubMed  CAS  Google Scholar 

  11. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, et al. A sudden increase in factor VIII inhibitor development in multitrans- fused hemophilia A patients in the Netherlands: Dutch Hemophilia Study Group.Blood. 1993;81:2180–2186.

    PubMed  CAS  Google Scholar 

  12. Schwarzinger I, Pabinger I, Korninger C, et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates.Am J Hematol. 1987;24:241–245.

    Article  PubMed  CAS  Google Scholar 

  13. Colvin BT, Hay CRM, Hill FGH, Preston FE. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93: Inhibitor Working Party. United Kingdom Haemophilia Centre Directors Organization.Br J Haematol. 1995;89:908–910.

    Article  PubMed  CAS  Google Scholar 

  14. Shima M. Mechanism of the inhibitor development and management in patients with hemophilia [in Japanese].Nihon Shouni Ketsueki Gakkai Zasshi. 1999;13:399–409.

    Google Scholar 

  15. Abe T, Igata A, Ikematsu S, et al. Multcenter clinical effect of heat- treated factor VIII (CP-8) preparation for patients with hemophilia A [in Japanese].Rinshio to Kenkyu. 1985;62:3640–3659.

    Google Scholar 

  16. Fujimaki M, Tanaka A, Fukutake K, et al. Clinical evaluation of recombinant factor VIII (BL-160) in patients with hemophilia A [in Japanese].Nihon Kessen Shiketsu Gakkaishi. 1993;4:179–188.

    Article  Google Scholar 

  17. Fujimaki M, Goto M, Miyazaki T, et al. Clinical study of FVIII concentrate highly purified by monoclonal antibodies to FVIII(RCG- 11) [in Japanese].Kiso to Rinsho. 1992;26:299–319.

    Google Scholar 

  18. Shima M. Hemophilia [in Japanese].Rinshoui. 2001;27:801–806.

    Google Scholar 

  19. Scharrer I, Bray GL, Neutzing O. Incidence of inhibitors in haemophilia A patients: a review of recent studies of recombinant and plasma-derived factor VIII concentrates.Haemophilia. 1999;5:145–154.

    Article  PubMed  CAS  Google Scholar 

  20. Lusher JM, Arkin S, Hurst D. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: update of safety, efficacy, and inhibitor development after seven study years.Thromb Haemost. 1997;77(suppl):162–163.

    Google Scholar 

  21. Gruppo R, Bray GL, Schroth P, Perry M, Gemperts ED. Safety and immunogenicity of recombinant factor VIII (RecombinateTM) in previously untreated patients (PUPs): a 6.5 year update.Thromb Haemost. 1997;77(suppl):162.

    Google Scholar 

  22. Addigo JE, Gomperts E. Jr, Liu SL, et al. Treatment of hemophilia A with a highly purified factor VIII concentrate prepared by anti-FVIIIc immunoaffinity chromatography.Thromb Haemost. 1992;67:19–27.

    Article  Google Scholar 

  23. Lusher JM. Viral safety and inhibitor development associated with monoclonal antibody-purified FVIIIC.Ann Hematol. 1991;63:138–141.

    Article  CAS  Google Scholar 

  24. Ingerslev J, Christiansen K, Ravn HB, Bray GL, Gomperts ED. Antibodies to heterologous proteins in hemophilia A patients receiving recombinant factor VIII (Recombinate).Thromb Haemost. 2002;87: 626–634.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Nara Medical University, Shijo-cho 840, Kashihara, 634-8522, Nara, Japan

    A. Yoshioka

  2. Department of Clinical Laboratory Medicine, Tokyo Medical College, Tokyo

    K. Fukutake

  3. Department of Blood Transfusion, Internal Medicine I, Nagoya University School of Medicine, Nagoya

    J. Takamatsu

  4. Department of Pediatrics, University of Occupational and Environmental Health, Kitakyushu, Japan

    A. Shirahata

Authors
  1. A. Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Fukutake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Shirahata
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Kogenate Post-Marketing Surveillance Study Group

Corresponding author

Correspondence to A. Yoshioka.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03191331.

About this article

Cite this article

Yoshioka, A., Fukutake, K., Takamatsu, J. et al. Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia A. Int J Hematol 78, 467–474 (2003). https://doi.org/10.1007/BF02983823

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02983823

Key words

Search

Navigation